Oxybutynin

What it is

Oxybutynin is a synthetic, racemic antispasmodic drug. It is sold as oxybutynin chloride, a white crystalline powder taken as a tablet, syrup, extended-release tablet, skin patch or gel. It blocks the action of acetylcholine at muscarinic receptors and so relaxes bladder smooth muscle. It is not a nutrient and is not found in food.

What the research says

For an overactive bladder, systematic reviews of randomised trials find that antimuscarinics including oxybutynin produce real but small average improvements in leakage and urinary frequency compared with placebo, with dry mouth two to three times more common on the drug. Oxybutynin is the oldest and most anticholinergic of the class: randomised studies in older adults show measurable short-term memory impairment, and large cohort and case-control studies link long cumulative bladder-antimuscarinic exposure with a higher rate of later dementia diagnosis - an association, not a demonstrated cause. It is also used off-label for excessive sweating and for hot flushes. The hot-flush evidence is one 150-woman randomised trial that was positive; the pooled review of sweating trials cannot be read for an effect size, because its abstract prints the same risk ratio for its benefit outcome and for dry mouth.

Evidence grade: Limited evidence.

How it works

Drug class: Antimuscarinic (anticholinergic) antispasmodic; non-selective muscarinic receptor antagonist used for bladder overactivity

Oxybutynin blocks muscarinic (acetylcholine) receptors on bladder smooth muscle and has a direct antispasmodic action. That raises the volume the bladder can hold, reduces involuntary detrusor contractions and delays the first urge to pass urine. Because muscarinic receptors are everywhere in the body, the same blockade also causes dry mouth, constipation, blurred vision and, by crossing into the brain, confusion and memory effects. (Source 1)

What it is used for

• Pooled randomised trials of antimuscarinics against placebo in overactive bladder show a higher chance of cure or improvement (RR 1.39) but only about half a leakage episode and two-thirds of a void less per 24 hours. One large systematic review called the size of these differences of questionable clinical significance, and no trial reported long-term outcomes. Evidence: limited. (Source 2)
• The off-label use rests on one 2023 systematic review and meta-analysis of six small placebo-controlled trials, 293 patients in all. No effect size can be taken from it: its published abstract prints the identical risk ratio, confidence interval and p-value for both its severity-score outcome and for dry mouth, and its dry-mouth sentence says there is no difference while printing a statistically significant result. The review itself says more clinical trials are needed. Evidence: unknown. (Source 3)
• In a 150-woman randomised double-blind trial, both oxybutynin doses cut weekly hot-flush scores more than placebo (-16.9 and -10.6 vs -5.7, P < .005), at the cost of more dry mouth, difficulty urinating and abdominal pain. It is one trial, six weeks long. Evidence: limited. (Source 4)

Interactions

• Ketoconazole and other strong CYP3A4 inhibitors (itraconazole, miconazole, erythromycin, clarithromycin) (pharmacokinetic study): Blood levels of oxybutynin rise three to four fold with ketoconazole, which would be expected to increase dry mouth, constipation and confusion. (Source 5)
• Other anticholinergic medicines and other agents that produce anticholinergic effects (sedating antihistamines, tricyclic antidepressants) (label): Adding anything else with anticholinergic action increases dry mouth, constipation and drowsiness. The dementia-association studies measured exactly this kind of cumulative total burden, not oxybutynin alone. (Source 5)
• Alcohol (label): Alcohol adds to the drowsiness oxybutynin causes. This is a label statement, not a measured interaction study. (Source 6)
• Hot weather and hot environments (not a supplement, but the commonest avoidable harm) (label): Oxybutynin reduces sweating, so fever and heat stroke can occur in high environmental temperature. Worth knowing alongside anything else that raises body temperature. (Source 6)
• Grapefruit and grapefruit juice (theoretical): No study of grapefruit with oxybutynin was found. The expectation that it would raise levels rests only on oxybutynin being a CYP3A4 substrate; the label itself says the clinical relevance of CYP3A4-inhibitor interactions is not known. (Source 5)
• Cholinesterase inhibitors for dementia (donepezil, rivastigmine, galantamine) (label): Oxybutynin works against these drugs; the label warns of aggravation of symptoms in people with pre-existing dementia taking them. (Source 7)
• Botanical products containing antimuscarinic alkaloids (for example belladonna, datura, henbane) (theoretical): No study of oxybutynin taken with any specific botanical product was found. The label makes only a general statement, that other agents producing anticholinergic-like effects can increase how often and how severely those effects occur, so a botanical carrying antimuscarinic alkaloids would be expected to add to the same load. That is mechanistic expectation, not a documented interaction with oxybutynin, and no botanical is named in the label. (Source 5)

Stopping it

• There is no described withdrawal syndrome. What the evidence shows instead is symptom return: in a randomised multicentre trial, 65% of women who had responded asked for retreatment and 62% relapsed within three months of stopping, regardless of whether they had taken the drug for 1, 3 or 6 months. (Source 8)
• Stopping is common in practice rather than planned: two-thirds of nursing-home residents stopped their antimuscarinic during their stay. (Source 9)
• For the cognitive effects specifically, the label's position is that dose reduction or drug discontinuation should be considered if anticholinergic CNS effects appear, and that patients should be monitored particularly in the first few months. (Source 7)

What goes wrong

Dry mouth is the dominant adverse effect, two to three times more frequent than with placebo in pooled trials. (Source 2)

• Systematic review, Moderate certainty.
• Size: 11,956 adults across 61 trials.
• Who: Adults with overactive bladder syndrome.
• How long: Trial duration (mostly weeks)
• Result: Dry mouth RR 3.00 (95% CI 2.70 to 3.34); withdrawal RR 1.11 (95% CI 0.91 to 1.36), not significant.
• Funding: not stated.

Limit of this finding: Two things to know about this review. Its abstract says "Nine medications were tested" and then lists eight names - it only reaches nine if emepronium bromide and emepronium carrageenate are counted separately - so the count should not be taken as checked. And it is a 2006 review: trials and drugs published since are not in it, so these pooled figures are not a current picture of the class.

There was three times the rate of dry mouth in the medication group (RR 3.00 95% CI 2.70 to 3.34) but no statistically significant difference in withdrawal (RR 1.11, 95% CI 0.91 to 1.36).

In the manufacturer's own trials of immediate-release oxybutynin tablets, dry mouth was reported by about seven in ten patients. (Source 10)

• Official position, Certainty not rated.
• Size: 199 patients in three clinical trials.
• Who: Patients treated with oxybutynin chloride 5 to 20 mg/day.
• How long: Up to 6 weeks.
• Result: Label table: dry mouth 71.4%, dizziness 16.6%, constipation 15.1%, somnolence 14.0%, nausea 11.6%, blurred vision 9.6% (single-arm incidences, no placebo column)
• Funding: industry (sponsor-submitted label data)

The most common adverse events reported by patients receiving oxybutynin chloride 5 to 20 mg/day were the expected side effects of anticholinergic agents. The incidence of dry mouth was dose-related.

In a randomised double-blind trial in healthy adults aged 60 and over, oxybutynin extended-release caused measurable memory impairment versus placebo while darifenacin did not, and participants did not notice it. (Source 11)

• Randomized trial, Moderate certainty.
• Size: 150 healthy subjects aged 60 or over.
• Who: Healthy older volunteers, not bladder patients.
• How long: 3 weeks.
• Result: Name-Face Association Test delayed recall: oxybutynin ER vs placebo mean difference -1.30 (p=0.011); vs darifenacin -1.24 (p=0.022); darifenacin vs placebo -0.06 (p=0.908)
• Funding: industry-funded (darifenacin manufacturer comparison study)

In contrast, oxybutynin ER resulted in memory impairment, with significantly lower scores than placebo and darifenacin (mean differences, -1.30, p=0.011 and -1.24, p=0.022, respectively) for delayed recall on the Name-Face Association Test at week 3.

An earlier crossover trial found single doses of oxybutynin produced significant cognitive decrements in older volunteers on about half the tests used. (Source 12)

• Randomized trial, Low certainty.
• Size: 12 volunteers, average age 69.17 years.
• Who: Normal community-dwelling older volunteers.
• How long: Single-dose test sessions one week apart.
• Result: Significant decrements on 7 of 15 cognitive measures with oxybutynin (5 and 10 mg) versus 5 of 15 with diphenhydramine 50 mg.
• Funding: independent (US Public Health Service support)

Random regression analyses demonstrated that oxybutynin caused significant cognitive decrements on seven of 15 cognitive measures, and diphenhydramine caused decrements on five measures.

A nested case-control analysis covering 284,343 people in all - 58,769 with a dementia diagnosis and 225,574 matched controls - found that the heaviest cumulative prescribing of bladder antimuscarinics was associated with about 65% higher odds of a later dementia diagnosis. (Source 13)

• Case-control study, Low certainty.
• Size: 58,769 dementia cases and 225,574 matched controls aged 55 or over.
• Who: English primary-care patients in the QResearch database.
• How long: Exposure measured 1 to 11 years before diagnosis.
• Result: Bladder antimuscarinic drugs adjusted OR 1.65 (95% CI 1.56 to 1.75) for more than 1095 total standardised daily doses; overall anticholinergic exposure OR rose from 1.06 (1.03-1.09) to 1.49 (1.44-1.54); population-attributable fraction 10.3%.
• Funding: independent (NIHR-supported academic study)

Limit of this finding: The 284,343 figure is the combined total of people with a dementia diagnosis and their matched controls, not a cohort followed over time and not a number of dementia cases. The source prints it with a narrow space between the digit groups ("284 343"), which can be misread as two numbers. Because this is a case-control analysis of prescribing records, it shows an association only.

There were significant increases in dementia risk for the anticholinergic antidepressants (adjusted OR [AOR], 1.29; 95% CI, 1.24-1.34), antiparkinson drugs (AOR, 1.52; 95% CI, 1.16-2.00), antipsychotics (AOR, 1.70; 95% CI, 1.53-1.90), bladder antimuscarinic drugs (AOR, 1.65; 95% CI, 1.56-1.75), and antiepileptic drugs (AOR, 1.39; 95% CI, 1.22-1.57) all for more than 1095 TSDDs.

A prospective cohort reported a dose-response relationship between cumulative strong anticholinergic use - most commonly bladder antimuscarinics among them - and incident dementia. (Source 14)

• Cohort study, Low certainty.
• Size: 3,434 participants aged 65 or over without dementia at entry.
• Who: Adult Changes in Thought cohort, Seattle.
• How long: Mean follow-up 7.3 years; 10-year cumulative exposure window.
• Result: Adjusted HR for dementia 1.54 (95% CI 1.21 to 1.96) at more than 1095 total standardised daily doses versus non-use; 0.92 (0.74-1.16), 1.19 (0.94-1.51) and 1.23 (0.94-1.62) in the lower bands; test for trend P < .001.
• Funding: independent (NIH extramural support)

A 10-year cumulative dose-response relationship was observed for dementia and Alzheimer disease (test for trend, P < .001). For dementia, adjusted hazard ratios for cumulative anticholinergic use compared with nonuse were 0.92 (95% CI, 0.74-1.16) for TSDDs of 1 to 90; 1.19 (95% CI, 0.94-1.51) for TSDDs of 91 to 365; 1.23 (95% CI, 0.94-1.62) for TSDDs of 366 to 1095; and 1.54 (95% CI, 1.21-1.96) for TSDDs greater than 1095.

Angioedema, sometimes after the first dose and sometimes involving the airway, is a recognised rare harm. (Source 15)

• Official position, Certainty not rated.
• Size: Postmarketing reports, denominator not given.
• Who: People taking oxybutynin.
• How long: Can occur after the first dose.
• Result: No rate is given; the label states airway involvement may be life-threatening.
• Funding: industry (sponsor label)

Angioedema of the face, lips, tongue and/or larynx has been reported with oxybutynin. In some cases, angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life-threatening.

Most people prescribed an antimuscarinic for overactive bladder in nursing homes stop it; oxybutynin was the most commonly prescribed agent in that setting. (Source 9)

• Cohort study, Low certainty.
• Size: 11,012 long-term nursing home residents.
• Who: Medicare beneficiaries with overactive bladder, mean age 81.6 years.
• How long: Mean nursing-home stay 530.1 days.
• Result: 66.5% discontinued the index antimuscarinic (gap of 30 days or more); oxybutynin accounted for 69.8% of prescriptions.
• Funding: industry-funded (the Europe PMC record for this paper lists Astellas Pharma US as the funder)

The most commonly prescribed OAB-specific antimuscarinic was oxybutynin (69.8%). Overall, 66.5% of the study cohort discontinued the index antimuscarinic.

What the evidence supports

Pooled randomised trials show antimuscarinics including oxybutynin beat placebo in overactive bladder, but the average change in leakage and voiding is under one episode per day. (Source 2)

• Systematic review, Moderate certainty.
• Size: 11,956 adults across 61 trials.
• Who: Adults with overactive bladder syndrome.
• How long: Most trials a few weeks; no long-term data.
• Result: Cure or improvement RR 1.39 (95% CI 1.28 to 1.51); leakage episodes per 24 h WMD -0.54 (95% CI -0.67 to -0.41); voids per 24 h WMD -0.69 (95% CI -0.84 to -0.54)
• Funding: not stated.

Limit of this finding: Two things to know about this review. Its abstract says "Nine medications were tested" and then lists eight names - it only reaches nine if emepronium bromide and emepronium carrageenate are counted separately - so the count should not be taken as checked. And it is a 2006 review: trials and drugs published since are not in it, so these pooled figures are not a current picture of the class.

At the end of the treatment period, cure or improvement (relative risk (RR) 1.39, 95% CI 1.28 to 1.51), difference in leakage episodes in 24 hours (weighted mean difference (WMD) -0.54; 95% CI -0.67 to -0.41) and difference in number of voids in 24 hours (WMD -0.69; 95% CI -0.84 to -0.54) were statistically significant favouring medication.

Oxybutynin reduced hot flushes more than placebo in a randomised double-blind trial, with more anticholinergic side effects but no excess of stopping for them. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 150 women with 28 or more hot flushes per week.
• Who: Peri- and postmenopausal women, 65% on tamoxifen or an aromatase inhibitor.
• How long: 6 weeks.
• Result: Weekly hot-flush score change: -16.9 (SD 15.6) on 5 mg twice daily, -10.6 (SD 7.7) on 2.5 mg twice daily, -5.7 (SD 10.2) on placebo; P < .005 for both doses.
• Funding: not stated (academic cooperative-group trial, ACCRU SC-1603)

Limit of this finding: The published abstract's hot-flush-score sentence has unbalanced brackets - it closes a parenthesis that was never opened, right before the placebo value - so the placebo figure of -5.7 (SD 10.2) can easily be read as belonging to the 2.5 mg arm. The three values are -16.9 on 5 mg twice daily, -10.6 on 2.5 mg twice daily and -5.7 on placebo.

Patients on both oxybutynin arms reported more side effects than patients on placebo, particularly dry mouth, difficulty urinating, and abdominal pain. Most side effects were grade 1 or 2. There were no differences in study discontinuation because of adverse effects.

What the evidence does not support

A BMJ systematic review concluded the differences between anticholinergics and placebo in overactive bladder were small and may be of questionable clinical significance. (Source 16)

• Systematic review, Low certainty.
• Size: 6,800 participants across 32 trials.
• Who: Adults with overactive bladder syndrome.
• How long: End of treatment; no long-term follow-up.
• Result: Cure or improvement RR 1.41 (95% CI 1.29 to 1.54); 0.6 fewer incontinent episodes and 0.6 fewer voids per 24 h.
• Funding: independent (UK academic review)

Although statistically significant, the differences between anticholinergic drugs and placebo were small, apart from the increased rate of dry mouth in patients receiving active treatment. For many of the outcomes studied, the observed difference between anticholinergics and placebo may be of questionable clinical significance.

The primary cognitive endpoint of that topical-gel trial was null for both oxybutynin arms, so it does not show the oral form is safe on recent memory, only that this one test did not separate the groups. (Source 17)

• Randomized trial, Low certainty.
• Size: 152 healthy adults aged 60-79.
• Who: Healthy older adults.
• How long: 1 week.
• Result: Name-Face Association Test delayed recall: overall p = 0.2733; gel vs placebo p = 0.1551; oral IR vs placebo p = 0.1767.
• Funding: industry-funded.

NFAT Delayed Recall tests revealed no significant treatment differences (overall, p = 0.2733; OTG vs placebo, p = 0.1551; OXB-IR vs placebo, p = 0.1767).

Where the evidence is mixed

The same Cochrane review states it is unknown whether any benefit lasts during long-term treatment or after stopping. (Source 18)

• Systematic review, Low certainty.
• Size: 11,956 adults across 61 trials.
• Who: Adults with overactive bladder syndrome.
• How long: Not assessed beyond trial length.
• Result: No quantitative long-term estimate was available.
• Funding: not stated.

It is not clear whether any benefits are sustained during long-term treatment or after treatment stops.

Route matters for the anticholinergic burden: in a randomised comparison, dry mouth occurred in 73.1% on oral immediate-release oxybutynin versus 6.1% on the topical gel and 7.8% on placebo. (Source 17)

• Randomized trial, Moderate certainty.
• Size: 152 healthy adults aged 60-79 (49 gel, 52 oral, 51 placebo)
• Who: Healthy older adults.
• How long: 1 week.
• Result: Dry mouth 6.1% (gel), 73.1% (oral IR), 7.8% (placebo); primary delayed-recall endpoint showed no significant treatment differences (overall p = 0.2733), but Misplaced Objects Test scores declined only with oral oxybutynin (p = 0.0294)
• Funding: industry-funded (topical gel manufacturer study)

The most common adverse event, dry mouth, occurred in 6.1%, 73.1% and 7.8% of participants receiving OTG, OXB-IR and placebo, respectively.

Where the research disagrees

Whether the average benefit of antimuscarinics in overactive bladder is clinically meaningful

• Cochrane review authors (2006), systematic review of 61 trials, 11,956 adults: The use of anticholinergic drugs by people with overactive bladder syndrome results in statistically significant improvements in symptoms. Recent trials suggest that this is associated with modest improvement in quality of life. (Source 18)
• Herbison and colleagues, BMJ (2003), systematic review of 32 trials, 6,800 participants: Although statistically significant, the differences between anticholinergic drugs and placebo were small, apart from the increased rate of dry mouth in patients receiving active treatment. (Source 16)

Whether oxybutynin impairs cognition in older people

• Kay and colleagues, European Urology (2006), 3-week randomised double-blind trial in 150 healthy adults aged 60 or over: In contrast, oxybutynin ER resulted in memory impairment, with significantly lower scores than placebo and darifenacin (mean differences, -1.30, p=0.011 and -1.24, p=0.022, respectively) (Source 11)
• The topical-gel trial investigators (2012), 1-week randomised placebo- and active-controlled trial in 152 healthy adults aged 60-79; primary endpoint null for both arms: NFAT Delayed Recall tests revealed no significant treatment differences (overall, p = 0.2733; OTG vs placebo, p = 0.1551; OXB-IR vs placebo, p = 0.1767) (Source 17)

How much

• Reference intake: Dosing is set by the prescriber, not the reader. As a position, the US label for immediate-release oxybutynin chloride tablets (version effective 2026-07-21) states the usual adult dose is one 5 mg tablet two to three times a day, with a lower start of 2.5 mg two or three times a day for the frail elderly, and one 5 mg tablet twice a day for children over 5 years. (Source 19)
• Upper limit: The same label states a maximum of one 5 mg tablet four times a day in adults (20 mg/day) and one 5 mg tablet three times a day in children over 5 years. This is a regulatory maximum, not a target. (Source 19)
• Studied: The pivotal label trials gave oxybutynin chloride 5 to 20 mg/day for up to 6 weeks to 199 patients. (Source 20)
• Studied: The memory trial in healthy older adults gave oxybutynin ER 10 mg once daily rising to 15 mg then 20 mg once daily by week 3. (Source 21)
• Studied: The hot-flush trial gave oral oxybutynin 2.5 mg twice a day or 5 mg twice a day for 6 weeks. (Source 4)

A common belief, and what the research shows

The belief: Oxybutynin is a mild, local bladder medicine, so its side effects stay in the bladder.

What the research shows: It is a non-selective antimuscarinic that reaches the brain. A randomised trial in healthy older adults found oxybutynin extended-release caused significant memory deterioration against placebo while a more bladder-selective drug did not, and that people did not realise it was happening: "No between-treatment differences were detected in self-rated memory, demonstrating that subjects were unaware of memory deterioration." Large observational studies of cumulative bladder-antimuscarinic exposure report higher later dementia rates (adjusted OR 1.65, 95% CI 1.56 to 1.75 at the highest exposure band), though observational data cannot show cause.

Questions and answers

What is it?

Oxybutynin is a synthetic antispasmodic drug, sold as oxybutynin chloride - a white crystalline powder made into tablets, syrup, extended-release tablets, a skin patch and a gel. Its therapeutic category on the label is antispasmodic, anticholinergic. It is a manufactured medicine, not a nutrient or a food component. (Source 22)

What does it do in the body?

It blocks the action of acetylcholine at muscarinic receptors on smooth muscle and relaxes the bladder. In people with involuntary bladder contractions, bladder-pressure studies show it increases how much the bladder holds, reduces uninhibited detrusor contractions and delays the first urge to pass urine. The same receptor blockade elsewhere in the body produces dry mouth, constipation, blurred vision and central effects. (Source 1)

Is it good or bad for you?

It depends on how much benefit a given person gets and how much anticholinergic load they can carry. Pooled trials show a genuine but small average effect - about half a leakage episode fewer per day - with dry mouth three times as common as on placebo. In older adults the harms side grows: a randomised trial found memory deterioration, and large cohorts and case-control studies associate heavy cumulative bladder-antimuscarinic use with later dementia diagnoses. A BMJ review judged the drug-placebo difference to be of questionable clinical significance for many outcomes. (Source 23)

How do you get more of it?

Oxybutynin is a prescription-only medicine; the amount in the body is set by the prescribed dose and route, not by diet or behaviour. Levels are also raised sharply by strong CYP3A4 inhibitors: ketoconazole raised mean oxybutynin plasma concentrations three to four fold. That is a drug interaction, not a way to get more of it. (Source 5)

If it is harmful, what reduces it?

Stopping the drug is what reduces it; oxybutynin is eliminated in hours, and the cognitive effects of anticholinergics are generally considered reversible on discontinuation. The label's position is that if anticholinergic central nervous system effects appear, dose reduction or stopping should be considered. Switching from oral to the topical gel sharply cut dry mouth in a randomised comparison (6.1% versus 73.1%). (Source 7)

Why might someone be low in it or missing it?

This question does not apply in the nutrient sense: nobody is naturally low in oxybutynin. People stop having it in their system because they stop taking it, and that is extremely common - two-thirds of nursing-home residents with overactive bladder discontinued their antimuscarinic during their stay. Reduced absorption or faster clearance from CYP3A4 inducers can also lower levels. (Source 9)

Which whole foods contain it or feed it?

No whole food contains oxybutynin. It is a manufactured racemic chemical, d,l-4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride, formulated with pharmaceutical excipients for oral administration. Food matters only in that alcohol adds to its drowsiness and heat exposure is riskier because the drug reduces sweating. (Source 22)

What happens if you do not have it?

Nothing happens from not having oxybutynin - it is a treatment, not something the body needs. For someone who was taking it and responding, stopping brings the bladder symptoms back: in a randomised trial, 65% of responders asked for retreatment and 62% relapsed within three months of stopping, whatever the previous treatment length. (Source 8)

How can you test for it?

There is no routine blood test used to guide oxybutynin treatment. What is measured instead is the condition and the harm: bladder-pressure (cystometric) studies were the objective measure in the trials, symptom diaries of leakage and voids per 24 hours were the outcomes pooled in the systematic reviews, and cognitive testing is what detected the memory effect in older adults - the Name-Face Association Test, with participants unable to detect the change themselves. (Source 2)

We searched: Searched Europe PMC for oxybutynin therapeutic drug monitoring, plasma concentration monitoring and cognitive screening trials, and read the full US label; no validated monitoring assay or recommended test is described. The closest objective measures in the literature are urodynamic endpoints and formal cognitive batteries.

References

1. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
2. Cochrane Database of Systematic Reviews. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.. 2006. PMID 17054185, DOI 10.1002/14651858.CD003781.pub2. Read the source
3. Archives of Dermatological Research. Safety and efficacy of oxybutynin in patients with hyperhidrosis: systematic review and meta-analysis of randomized controlled trials - Results section of the published abstract. 2023. PMID 36869926, DOI 10.1007/s00403-023-02587-5. Read the source
4. JNCI Cancer Spectrum. Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603).. 2020. PMID 32337497, DOI 10.1093/jncics/pkz088. Read the source
5. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
6. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
7. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
8. International Journal of Clinical Practice. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial.. 2011. PMID 21849011, DOI 10.1111/j.1742-1241.2011.02728.x. Read the source
9. Advances in Therapy. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.. 2020. PMID 32638205, DOI 10.1007/s12325-020-01412-z. Read the source
10. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
11. European Urology. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.. 2006. PMID 16687205, DOI 10.1016/j.eururo.2006.03.057. Read the source
12. Journal of the American Geriatrics Society. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride - Results section of the published abstract. 1998. PMID 9434659, DOI 10.1111/j.1532-5415.1998.tb01006.x. Read the source
13. JAMA Internal Medicine. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study.. 2019. PMID 31233095, DOI 10.1001/jamainternmed.2019.0677. Read the source
14. JAMA Internal Medicine. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.. 2015. PMID 25621434, DOI 10.1001/jamainternmed.2014.7663. Read the source
15. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
16. BMJ. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.. 2003. PMID 12702614, DOI 10.1136/bmj.326.7394.841. Read the source
17. Clinical Drug Investigation. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study.. 2012. PMID 22909146, DOI 10.1007/BF03261924. Read the source
18. Cochrane Database of Systematic Reviews. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.. 2006. PMID 17054185, DOI 10.1002/14651858.CD003781.pub2. Read the source
19. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
20. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
21. European Urology. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects - Methods section of the published abstract. 2006. PMID 16687205, DOI 10.1016/j.eururo.2006.03.057. Read the source
22. DailyMed / US FDA Structured Product Label, label version effective 2026-07-21. OXYBUTYNIN CHLORIDE TABLET - prescribing information (Rising Pharma Holdings, Inc.). 2026. Read the source
23. BMJ. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review.. 2003. PMID 12702614, DOI 10.1136/bmj.326.7394.841. Read the source